MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study

On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. This amendment was developed to complete administrative and operational refinements in advance of study initiation. Amendment 4, Version 1 updates the previously cleared smoking-only protocol (A3V1) and was… Continue reading MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study